Modeling points to CYP2C19 as CBD’s key interaction concern
Integrating Static and Dynamic Models to Predict Cannabidiol-Mediated Metabolic Drug-Drug Interactions.
AI Summary
This study asked how well different modeling approaches predict CBD-related metabolic drug interactions. Researchers compared basic and mechanistic static models with a physiologically based pharmacokinetic (PBPK) model, incorporating CBD and its active metabolite, 7-OH-CBD. The work used in vitro inhibition data and clinical pharmacokinetic data to build and validate the PBPK model; it was a modeling study, not a trial testing CBD in participants.
The mechanistic static model predicted increases in exposure for sensitive substrates of CYP1A2, CYP2C9, and CYP3A4, and a strong interaction through CYP2C19. The validated PBPK model predicted lower interaction magnitudes more consistent with clinical data: CYP2C19 was identified as the most clinically relevant concern, with moderate risk for sensitive substrates, while CYP1A2 inhibition was predicted to double exposure. The authors used the model to examine special populations and commonly co-prescribed medicines. Because these are model-based predictions and the abstract provides limited clinical DDI data, the study cannot establish the actual interaction risk for every medication or patient; this is an abstract-based summary, not a review of the full paper.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.